ライフサイエンス研究メディア

バイオマーケットjpはバイオ・ライフサイエンス研究に役立つ情報を発信するWebメディアです

Diverse effects of clarithromycin and proposal of its clinical application for treating COVID-19 as a repurposing drug


Posted: 2021-09-11 19:00:00
Outbreak of SARS-CoV-2 has been declared a pandemic, which is a serious threat to human health. The disease was named coronavirus disease 2019 (COVID-19). Until now, several vaccines and a few drugs have been approved for the prevention and treatment for COVID-19. Recently, the effect of some macrolides including clarithromycin (CAM) on COVID-19 has attracted attention. CAM is known to have diverse effects including immunomodulatory and immunosuppressive effects, autophagy inhibition, steroid sparing effect, reversibility of drug resistance, antineoplastic effect, antiviral effect as well as bacteriostatic/bactericidal effect. Many patients with COVID-19 died due to an overwhelming response of their own immune system characterized by the uncontrolled release of circulating inflammatory cytokines (cytokine release syndrome [CRS]). This CRS plays a major role in progressing pneumonia to acute respiratory distress syndrome (ARDS) in COVID-19 patients. It is noteworthy that CAM can suppress inflammatory cytokines responsible for CRS and also has anti-SARS-CoV-2 effect. Considering the rapidly progressive global disease burden of COVID 19, the application of CAM for treating COVID-19 needs to be urgently evaluated. Recently, an open-labeled non-randomized trial using CAM for treating COVID-19 (ACHIEVE) was initiated in Greece in May, 2020. Its results, though preprint, indicated that CAM treatment of patients with moderate COVID-19 was associated with early clinical improvement and containment of viral load. Thus, treatment with CAM as a single agent or combined with other anti-SARS CoV-2 drugs should be tried for treating COVID-19. In this article, we discussed the significance and usefulness of CAM in treating COVID-19.

参考サイト PubMed: covid-19




バイオクイックニュース日本語版:COVID-19特集

バイオクイックニュース日本語版
7月 10, 2020 bioassociates2

血液型とCOVID-19の重篤化リスクについての関連性がNEJMで発表

2020年6月18日、NIHのディレクターであるFrancis Collins 医学博士は、血液型と重度の COVID-19 のリスクについてブログに投稿した。 本記事は、そのブログの内容に基づいている 。 Collins 博士のブログのタイトルは「遺伝子、血液型は深刻なCOVID-19のリスクに結びついている(Genes, Blood Type Tied to Risk of Severe COVID-19.)」…

ゲスト 203人 と メンバー 2人 がオンラインです